Several complement proteins, including C3, C5, and C1q, have been implicated in atherogenesis, suggesting a potential avenue for targeted therapies to mitigate CVD risk in the general population and specifically in patients with SLE [55]. The gene discussed is VTN; the disease is systemic lupus erythematosus.